20:04 , Apr 20, 2018 |  BC Week In Review  |  Company News

ApolloBio licenses Tocagen's immunotherapy

Tocagen Inc. (NASDAQ:TOCA) granted ApolloBio Corp. (NEEQ:430187) exclusive rights to develop and commercialize vocimagene amiretrorepvec/extended release flucytosine (Toca 511/Toca FC) in Taiwan and China, including Hong Kong and Macau, to treat high grade glioma (HGG)....
23:20 , Mar 1, 2018 |  BC Innovations  |  Targets & Mechanisms

Checking out the microbiome

What started out as a potential use in stratifying patients is growing into a new avenue for turning non-responders to responders, as evidence continues to emerge linking the microbiome to immuno-oncology. While the data are...
20:17 , Nov 3, 2017 |  BC Week In Review  |  Clinical News

Tocagen reports Phase I data for glioma candidate, moves to Phase III

Tocagen Inc. (NASDAQ:TOCA) reported data from 53 evaluable patients with recurrent high-grade glioma in a Phase I trial showing that vocimagene amiretrorepvec/extended release flucytosine (Toca 511/Toca FC) led to a clinical benefit rate (CBR) of...
19:01 , Jul 5, 2017 |  BC Extra  |  Financial News

Microbiome company Anaeropharma raises $13.2M

Microbiome and cancer play Anaeropharma Science Inc. (Tokyo, Japan) raised $13.2 million from new investors Novartis AG (NYSE:NVS; SIX:NOVN), Shinsei Corporate Investment and Seventure Partners’ Health for Life Capital. Existing investors Innovation Network Corp. of...
19:46 , Apr 13, 2017 |  BC Extra  |  Financial News

Tocagen rises after $85M IPO

Tocagen Inc. (NASDAQ:TOCA) climbed $2.45 (25%) to $12.45 in its first day of trading Thursday after it raised $85 million through the sale of 8.5 million shares at $10 in an IPO underwritten by Leerink,...
22:48 , Mar 30, 2017 |  BioCentury  |  Emerging Company Profile

Resisting resistance

While many companies are attempting to counteract mutations in cancer that result in resistance, ApoGen Biotechnologies Inc. is instead targeting a mechanism that causes resistance mutations to develop. The approach could prolong responses to cancer...
23:12 , Mar 10, 2017 |  BC Extra  |  Financial News

Gene therapy company Tocagen proposes $86.3M IPO

Tocagen Inc. (San Diego, Calif.) proposed to raise up to $86.3 million in an IPO on NASDAQ underwritten by Leerink, Evercore and Stifel. The gene therapy company expects to report top-line results in 1H18 from...
02:21 , Feb 24, 2017 |  BC Week In Review  |  Clinical News

Toca 511/Toca FC regulatory update

Tocagen said FDA granted breakthrough therapy designation to Toca 511/Toca FC to treat recurrent high grade glioma. The product is a regimen of Toca 511, a retroviral replicating vector that delivers the cytosine deaminase gene,...
07:00 , Oct 3, 2016 |  BC Week In Review  |  Clinical News

Vocimagene amiretrorepvec/extended release flucytosine: Phase Ib started

Tocagen began the open-label, U.S. Phase Ib Toca 6 trial to evaluate 14 mL IV Toca 511 daily for 3 consecutive days or 0.1-4 mL intralesional Toca 511 daily for 5 consecutive days in about...
08:00 , Dec 21, 2015 |  BC Week In Review  |  Clinical News

Vocimagene amiretrorepvec/extended release flucytosine: Phase II/III started

Tocagen began an open-label, U.S. Phase II/III trial to evaluate Toca 511 given on day 1 after resection followed by oral Toca FC vs. standard of care in about 170 patients with first or second...